UA80957C2 - Method of administering a thymosin alpha 1 peptide - Google Patents
Method of administering a thymosin alpha 1 peptide Download PDFInfo
- Publication number
- UA80957C2 UA80957C2 UA20040504064A UA20040504064A UA80957C2 UA 80957 C2 UA80957 C2 UA 80957C2 UA 20040504064 A UA20040504064 A UA 20040504064A UA 20040504064 A UA20040504064 A UA 20040504064A UA 80957 C2 UA80957 C2 UA 80957C2
- Authority
- UA
- Ukraine
- Prior art keywords
- specified
- peptide
- patient
- indicated
- thymosin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 27
- 108010078233 Thymalfasin Proteins 0.000 title abstract 4
- 238000001802 infusion Methods 0.000 claims abstract description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 30
- 230000004936 stimulating effect Effects 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims description 41
- 108010046075 Thymosin Proteins 0.000 claims description 13
- 230000000694 effects Effects 0.000 claims description 12
- 230000003308 immunostimulating effect Effects 0.000 claims description 11
- 210000004698 lymphocyte Anatomy 0.000 claims description 11
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims description 11
- 102000004127 Cytokines Human genes 0.000 claims description 10
- 108090000695 Cytokines Proteins 0.000 claims description 10
- 102000007501 Thymosin Human genes 0.000 claims description 10
- 210000000265 leukocyte Anatomy 0.000 claims description 9
- 210000003714 granulocyte Anatomy 0.000 claims description 8
- 238000010254 subcutaneous injection Methods 0.000 claims description 6
- 239000007929 subcutaneous injection Substances 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 230000000638 stimulation Effects 0.000 abstract description 6
- 102400000800 Thymosin alpha-1 Human genes 0.000 abstract 2
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 abstract 2
- 229960004231 thymalfasin Drugs 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 241000700159 Rattus Species 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- MFRCZYUUKMFJQJ-UHFFFAOYSA-N 1,4-dioxane-2,5-dione;1,3-dioxan-2-one Chemical compound O=C1OCCCO1.O=C1COC(=O)CO1 MFRCZYUUKMFJQJ-UHFFFAOYSA-N 0.000 description 1
- 101100289989 Drosophila melanogaster alpha-Man-Ia gene Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101150021286 MAS1 gene Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000011342 chemoimmunotherapy Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- NBNNDUZYMXBCOX-UHFFFAOYSA-N n-[4-[4-(4-methoxyphenoxy)-2,6-dimethylphenyl]-1,3-thiazol-2-yl]pyridine-4-carboxamide Chemical compound C1=CC(OC)=CC=C1OC(C=C1C)=CC(C)=C1C1=CSC(NC(=O)C=2C=CN=CC=2)=N1 NBNNDUZYMXBCOX-UHFFFAOYSA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 108700016958 thymosin fraction 5 Proteins 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33087401P | 2001-11-01 | 2001-11-01 | |
| PCT/US2002/035093 WO2003037366A1 (en) | 2001-11-01 | 2002-11-01 | Method of administering a thymosin alpha 1 peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA80957C2 true UA80957C2 (en) | 2007-11-26 |
Family
ID=23291672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20040504064A UA80957C2 (en) | 2001-11-01 | 2002-01-11 | Method of administering a thymosin alpha 1 peptide |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20050049191A1 (ru) |
| EP (1) | EP1450850B1 (ru) |
| JP (1) | JP2005511563A (ru) |
| KR (1) | KR20050042229A (ru) |
| CN (1) | CN1582163A (ru) |
| AT (1) | ATE481980T1 (ru) |
| AU (1) | AU2002363248B2 (ru) |
| BR (1) | BR0213823A (ru) |
| CA (1) | CA2464307A1 (ru) |
| DE (1) | DE60237784D1 (ru) |
| EA (1) | EA008536B1 (ru) |
| ES (1) | ES2353379T3 (ru) |
| IL (2) | IL161665A0 (ru) |
| MX (1) | MXPA04004187A (ru) |
| NO (1) | NO327101B1 (ru) |
| NZ (1) | NZ532763A (ru) |
| PL (1) | PL208388B1 (ru) |
| UA (1) | UA80957C2 (ru) |
| WO (1) | WO2003037366A1 (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050086819A (ko) * | 2002-11-25 | 2005-08-30 | 시클론 파마수티컬 인코포레이티드 | 알파 티모신을 사용한 방사능 손상에 대한 보호방법 |
| BRPI0408892A (pt) * | 2003-03-28 | 2006-04-11 | Sciclone Pharmaceuticals Inc | uso de timosina alfa 1 para tratar as infecções por arpergillus |
| US8017129B2 (en) | 2006-06-15 | 2011-09-13 | SciClone Pharmaceuticals International Ltd | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma |
| US20080300166A1 (en) * | 2007-06-01 | 2008-12-04 | Sciclone Pharmaceuticals, Inc. | Treatment of Melanoma with Alpha Thymosin Peptides |
| AU2008338594A1 (en) * | 2007-12-14 | 2009-06-25 | Sciclone Pharmaceuticals, Inc. | Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (HSAA) |
| CN102458470B (zh) | 2009-05-08 | 2016-01-20 | 赛生制药有限公司 | 作为疫苗增强剂的α胸腺素肽 |
| WO2013134666A1 (en) * | 2012-03-08 | 2013-09-12 | Sciclone Pharmaceuticals, Inc. | Use of thymosin alpha for treatment of purulent rhinosinusitis |
| US20130296223A1 (en) | 2012-03-30 | 2013-11-07 | Sciclone Pharmaceuticals, Inc. | Use of thymosin alpha for the treatment of sepsis |
| ES2882080T3 (es) * | 2014-10-21 | 2021-12-01 | Sciclone Pharmaceuticals Int Ltd | Tratamiento del cáncer con estimuladores inmunitarios |
| EP3256150B1 (en) * | 2015-02-09 | 2020-12-09 | SciClone Pharmaceuticals International Ltd. | Thymosin alpha 1 for use in treatment of cystic fibrosis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447233A (en) * | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4444757A (en) * | 1981-11-16 | 1984-04-24 | Research Corporation | Use of thymosin as an anti-diabetes and anti-hypertensive disease agent |
| TW224053B (ru) * | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
| US5468729A (en) * | 1993-10-26 | 1995-11-21 | Alpha 1 Biomedicals | Method for treatment of autoimmune hepatitis |
| US5760000A (en) * | 1994-05-13 | 1998-06-02 | University Technologies International,Inc. | Inhibition of liver cancer by the use of GnRH and GnRH analogs |
| US5888980A (en) * | 1994-06-30 | 1999-03-30 | Bio-Logic Research And Development Corporation | Compositions for enhancing immune function |
| US5632983A (en) * | 1994-11-17 | 1997-05-27 | University Of South Florida | Method for treating secondary immunodeficiency |
| US5849596A (en) * | 1996-07-08 | 1998-12-15 | Food Industry Research And Development Institute | Process for determining the smoke content of edible oil |
| ATE342959T1 (de) * | 2000-07-14 | 2006-11-15 | Transform Pharmaceuticals Inc | System und verfahren zum optimieren des gewebebarrieretransfers von verbindungen |
| AU2002241596A1 (en) * | 2000-11-02 | 2002-06-18 | Research Foundation Of City University Of New York | Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4 |
-
2002
- 2002-01-11 UA UA20040504064A patent/UA80957C2/uk unknown
- 2002-11-01 CA CA002464307A patent/CA2464307A1/en not_active Abandoned
- 2002-11-01 EA EA200400591A patent/EA008536B1/ru not_active IP Right Cessation
- 2002-11-01 AT AT02802520T patent/ATE481980T1/de not_active IP Right Cessation
- 2002-11-01 IL IL16166502A patent/IL161665A0/xx active IP Right Grant
- 2002-11-01 ES ES02802520T patent/ES2353379T3/es not_active Expired - Lifetime
- 2002-11-01 JP JP2003539708A patent/JP2005511563A/ja active Pending
- 2002-11-01 US US10/493,848 patent/US20050049191A1/en not_active Abandoned
- 2002-11-01 NZ NZ532763A patent/NZ532763A/en not_active IP Right Cessation
- 2002-11-01 MX MXPA04004187A patent/MXPA04004187A/es active IP Right Grant
- 2002-11-01 DE DE60237784T patent/DE60237784D1/de not_active Expired - Lifetime
- 2002-11-01 KR KR1020047006674A patent/KR20050042229A/ko not_active Application Discontinuation
- 2002-11-01 EP EP02802520A patent/EP1450850B1/en not_active Expired - Lifetime
- 2002-11-01 CN CNA02821871XA patent/CN1582163A/zh active Pending
- 2002-11-01 BR BR0213823-9A patent/BR0213823A/pt not_active IP Right Cessation
- 2002-11-01 WO PCT/US2002/035093 patent/WO2003037366A1/en active Application Filing
- 2002-11-01 AU AU2002363248A patent/AU2002363248B2/en not_active Ceased
- 2002-11-01 PL PL370430A patent/PL208388B1/pl not_active IP Right Cessation
-
2004
- 2004-04-29 IL IL161665A patent/IL161665A/en not_active IP Right Cessation
- 2004-05-21 NO NO20042100A patent/NO327101B1/no not_active IP Right Cessation
-
2010
- 2010-05-07 US US12/775,986 patent/US20100221274A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL161665A0 (en) | 2004-09-27 |
| ATE481980T1 (de) | 2010-10-15 |
| NO20042100L (no) | 2004-05-21 |
| MXPA04004187A (es) | 2004-07-08 |
| ES2353379T3 (es) | 2011-03-01 |
| EA008536B1 (ru) | 2007-06-29 |
| EA200400591A1 (ru) | 2004-10-28 |
| US20100221274A1 (en) | 2010-09-02 |
| BR0213823A (pt) | 2004-08-31 |
| PL370430A1 (en) | 2005-05-30 |
| EP1450850B1 (en) | 2010-09-22 |
| AU2002363248B2 (en) | 2007-11-22 |
| NO20042100D0 (no) | 2004-05-21 |
| EP1450850A4 (en) | 2005-11-30 |
| US20050049191A1 (en) | 2005-03-03 |
| JP2005511563A (ja) | 2005-04-28 |
| WO2003037366A1 (en) | 2003-05-08 |
| PL208388B1 (pl) | 2011-04-29 |
| CA2464307A1 (en) | 2003-05-08 |
| DE60237784D1 (de) | 2010-11-04 |
| EP1450850A1 (en) | 2004-09-01 |
| CN1582163A (zh) | 2005-02-16 |
| NZ532763A (en) | 2008-01-31 |
| NO327101B1 (no) | 2009-04-20 |
| IL161665A (en) | 2011-03-31 |
| KR20050042229A (ko) | 2005-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100221274A1 (en) | Method of administering a thymosin alpha 1 peptide | |
| Talmadge et al. | Immunomodulatory and immunotherapeutic properties of recombinant γ-interferon and recombinant tumor necrosis factor in mice | |
| Cárdenas-Camarena et al. | Combined gluteoplasty: liposuction and lipoinjection | |
| JP4416839B2 (ja) | 二次性免疫不全症の治療法 | |
| AU698410B2 (en) | Use of interleukin-12 to prevent graft versus host disease | |
| Sayers et al. | Antitumor effects of α-interferon and γ-interferon on a murine renal cancer (Renca) in vitro and in vivo | |
| UA78726C2 (en) | Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment | |
| AU2008335840A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic T lymphocyte-associated antigen 4 (CTLA4) | |
| AU2002363248A1 (en) | Method of administering a Thymosin alpha 1 peptide | |
| AU2002353964A1 (en) | Thymosin alpha 1 peptide/polymer conjugates | |
| Marshall et al. | Continuous infusion of macrophage inflammatory protein MIP-1alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide | |
| Zeuzem | The American Association for the Study of Liver Diseases: new perspectives in the treatment of hepatitis C | |
| KR960014097B1 (ko) | 거대세포바이러스 망막염과 관련된 징후들을 치료하기 위한 조성물 | |
| MXPA05011304A (es) | Composiciones a base de peptidos de alfa timosina para el tratamiento y prevencion de infecciones virales respiratorias. | |
| AU2008200190A1 (en) | Method of Administering a Thymosin Alpha 1 Peptide | |
| Beniers et al. | In vivo antiproliferative effects of gamma-interferon and tumor necrosis factor alpha in a rat renal cell carcinoma model system | |
| JP2009091348A (ja) | がんの治療方法 | |
| Hirashima et al. | Induction of an eosinophil chemotactic factor production from T lymphocytes by a B cell lymphoma line | |
| Ohnishi et al. | Successful in vivo generation of canine lymphokine-activated killer cells by continuous recombinant interleukin-2 infusion through the splenic artery | |
| van Dijk | Delivery of biologicals: Sustained release of cell-specific proteins in fibrosis |